Opus Genetics, Inc. (IRD)

NASDAQ: IRD · USD

$3.68

+0.22 (+6.4%)· Recorded snapshot

Market cap	306.2M
Revenue (ttm)	9.9M
Net income (ttm)	-107.6M
EPS (ttm)	-$1.29
Shares out	83.2M
Volume	927,148
Beta	0.62

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 9.9M
Net income (ttm): -107.6M
EPS (ttm): -$1.29
Market cap: 306.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-4,796.5

P25 n/aP50 n/aP75 n/a

ROIC-70.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IRD indicators

Market & fundamental data

Available fields

191

Groups with data

Currency

USD

Showing 191 of 191 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001228627
Company name	Opus Genetics, Inc.
Country	United States
Country code	US
CUSIP number	67577R102
Earnings date	2026-11-11
Earnings time	bmo
Employees	28
Employees change	10
Employees growth	55.56%
Enterprise value	$253.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US67577R1023
Last 10-K release date	2026-03-12
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$306.2M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$3.68
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	IRD
U.S. state	North Carolina
Website	https://opusgtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-35.12%
EV/Sales	25.22x
FCF / EV yield	-16.36%
FCF yield	-13.5%
Forward EV/Sales	18.65x
Forward P/S	22.6x
P/S ratio	30.56x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-291.85%
Operating margin	-513.47%
Pretax margin	-1,091.82%
Profit per employee	$-3.8M
Revenue per employee	$352,000
ROA	-48.06%
ROA (5Y)	-29.93%
ROCE	-59.29%
ROE	-4,796.52%
ROE (5Y)	-331.7%
ROIC	-70.88%
SBC / revenue	45.26%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	-36.09%
Revenue growth (Q)	-73.8%
Revenue growth (QoQ)	-65%
Revenue growth 3Y	-39.84%
Revenue growth 5Y	150.46%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$53,000
EBIT	$-50.6M
EBITDA	$-50.6M
EPS	$-1.29
FCF per share	$-0.49
Financing cash flow	$97.2M
Free cash flow	$-40.7M
Free cash flow minus SBC	$-45.1M
Gross profit	$-28.8M
Net borrowing	$35M
Net cash flow	$56.5M
Net income	$-107.6M
Operating cash flow minus SBC	$-45.1M
Operating income	$-50.6M
Revenue	$9.9M
Stock-based compensation	$4.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.4
Book value per share	$-0.16
Interest coverage	-32.32
Long-term assets	$272,000
Long-term liabilities	$98.3M
Net cash (debt)	$52.6M
Net cash / market cap	17.47%
Net cash growth	67.39%
Piotroski F-Score	2
Property, plant and equipment	$172,000
Shareholders' equity	$-13M
Tangible book value	$-13M
Tangible book value per share	$-0.16
Total assets	$93M
Total cash	$88.8M
Total debt	$36.2M
Total liabilities	$106M
WACC	7.21%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.15
Current assets	$92.7M
Current liabilities	$7.6M
Current ratio	12.19
Net working capital	$-3.7M
Quick ratio	11.87
Working capital	$85.1M
Working capital turnover	0.19

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-116.9%
Dividend yield	0%
Shareholder yield	-116.9%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.36
1D price change	6.36%
1M price change	-25.53%
1M total return	-25.53%
1W price change	-11.6%
1W total return	-11.6%
1Y price change	77.25%
1Y return CAGR	77.32%
1Y total return	77.25%
20-day SMA	$4.09
200-day SMA	$4.17
3M price change	5.82%
3M total return	5.82%
3Y price change	28.44%
3Y return CAGR	8.7%
3Y total return	28.44%
50-day SMA	$4.48
50-day SMA vs 200-day SMA	50over200
52-week high	$7.07
52-week high date	2026-09-09
52-week low	$1.70
52-week low date	2025-11-18
5Y price change	-11.15%
5Y return CAGR	-2.34%
5Y total return	-11.15%
6M price change	-30.76%
6M total return	-30.76%
All-time high	$13.81
All-time high date	2021-02-03
All-time low	$0.65
All-time low date	2025-04-10
Average true range (ATR)	$0.34
Average volume	1.6M
Beta (1Y)	0.75
Beta (2Y)	0.64
Beta (5Y)	0.62
Change from 52-week high	-47.95%
Change from 52-week low	116.47%
Change from all-time high	-74.33%
Change from all-time low	445.38%
Change from open	7.92%
Day's gap	-1.45%
Dollar volume	$3.4M
High price	$3.68
Low price	$3.41
Monthly RSI	53.97
Open price	$3.41
Position in 52-week range	100%
Premarket change	0%
Premarket close	$3.46
Premarket price	$3.46
Previous close	$3.46
Price vs 150-day SMA	-18.77%
Price vs 20-day SMA	-13.33%
Price vs 200-day SMA	-14.93%
Price vs 50-day SMA	-20.94%
Relative volume	0.57
RSI	36.05
Sharpe ratio	1.04
Sharpe ratio (3Y)	0.41
Sharpe ratio (5Y)	0.27
Sortino ratio	1.89
Sortino ratio (3Y)	0.72
Sortino ratio (5Y)	0.5
Volume	927.1K
Weekly RSI	44.94
YTD price change	76.37%
YTD total return	76.37%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	64.7M
Float percentage	77.79%
Shares change (QoQ)	28.19%
Shares change (YoY)	116.9%
Shares held by insiders	7.66%
Shares held by institutions	58.64%
Shares outstanding	83.2M
Short % of float	20.11%
Short % of shares	15.64%
Short ratio	2.6 days

Deeper analysis on IRD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IRD report

Is a complete IRD research report available?

No complete published report is available for Opus Genetics, Inc. (IRD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Opus Genetics, Inc. (IRD)

Price

Financial snapshot

Fair-value bridge

Latest news · IRD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IRD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IRD

Frequently asked questions